Reapplix wins patent in US and Japan
The Danish medtech company Reapplix, which has invented a biological patch to treat diabetic foot ulcers, has moved one step closer to fulfilling its commercial ambitions.
BY HENRIK TÜCHSEN
One of the major new hopes on the Danish medtech scene, Reapplix, has recently won a patent for its main asset in both the US and Japan, the company writes in a press release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo-owned company faces generic competition
For abonnenter
Danish venture groups: We have turned a corner
For abonnenter
Novo Ventures follows dual investment approach
For abonnenter
